Easy Find It Page
Easy Find It
Use Our Mobile Site
Use Our Mobile Site
Share This Website
The Sugar Trehalose
Free NEWS Letter
Affiliate Program
Untitled Document

Already an Affiliate? Click on the link below to access your account-

Affiliate Login

Endowment Book Store
The Trehalose Store
Endowment Store Front
Support The Endowment
Enter Amount:
We Accept
VisaMaster CardAmerican ExpressDiscoverssl lock
Download Store

Download Store

Download 7 Free Newsletters Plus Other Educational Materials

Main Menu
- - - - - - -
Inside the Human Cell
The Sugar Trehalose
- - - - - - -
Sugar Science Forum
Glycomics Training
Interactive Glycomics Brochure
7 FREE NEWSletters
HOT Links of Interest
- - - - - - -
Contact Us
Educational e-textbook
Chapter One

Chapter One

FREE Sneek Peek
Chapter One

Evaluation Forms

Huntington’s General
Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

Parkinson's General
Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

Alzheimer / Dementia
General Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

Diabetic Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

General Public Health
Evaluation FORM for
Trehalose Nutritional
Pilot Survey (For General
Public without Huntington’s,
Alzheimer’s, or Parkinson’s.)

Who's Online
We have 32 guests online
Scientists claim proof of Alzheimer's breakthrough
Editor’s note:
Warning about the drug used in this report. We are posting this news because we wish to keep you informed of the latest discoveries involving brain function, especially Alzheimer’s. The fact that the neurons can be connected again is a good thing. This seems to verify that the problem was not with the neurons but the synapses. The Endowment for Medical Research has had two Alzheimer’s papers published and our motto is: Whatever works and does no harm. Here are the stated side effects of the drug used in this study.

GENERIC NAME: ETANERCEPT - INJECTION (ee-TAN-er-cept) BRAND NAME(S): Enbrel USES: This medication is used to treat certain types of arthritis (e.g., rheumatoid, psoriatic, and ankylosing spondylitis). It is also used to treat certain skin conditions (psoriasis).

HOW TO USE: Use this medication exactly as prescribed. This drug is given under the skin (SC) twice weekly or as directed. Learn all the preparation and administration instructions in the product package and ask your doctor or pharmacist if you are unclear on any information. Rotate injection sites. New injections should be given at least one inch from an old site. Do not inject into areas of the skin that are sore, bruised, red or hard. Do not use if the liquid contains particles or is discolored. Make sure needles and any medical supplies are stored safely and disposed of properly.

SIDE EFFECTS: Redness, itching, pain, or swelling at the injection site; colds; cough; headache; or nausea may occur. If these effects persist or worsen, notify your doctor promptly. Tell your doctor immediately if any of these unlikely but serious side effects occur: chest pain, stomach pain, trouble breathing, mental/mood changes, severe headache, signs of infections (e.g., persistent sore throat, fever), butterfly rash (i.e., rash on nose and cheeks), extreme fatigue. Tell your doctor immediately if any of these highly unlikely but very serious side effects occur: tingling of the hands or feet, unsteadiness, unexplained muscle weakness, seizures, vision changes, unusual bruising or bleeding. Though very unlikely, you may have a slight increased risk of developing cancer (e.g., lymphoma) to this medication. Tell your doctor immediately if you develop symptoms such as: unusual lumps/growths, swollen glands, night sweats, unexplained weight loss. An allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of an allergic reaction include: rash, itching, swelling, dizziness, trouble breathing. If you notice other effects not listed above, contact your doctor or pharmacist.

Independent.co.uk Web By Jeremy Laurance, Health Editor?Saturday, 12 April 2008

An injection that dramatically relieved the symptoms of Alzheimer's disease within minutes would qualify as the discovery of the decade. That is exactly what was claimed yesterday for an experimental treatment being tested in America.

Scientists at the Institute for Neurological Research at the University of California have treated around 50 patients at a private clinic by injecting an anti-arthritic drug, etanercept, into the spinal column in the neck and then tilting the patients to encourage the drug to flow to the brain.

hey claim 90 per cent respond to the treatment, usually within minutes, and have released videos of patients to prove it. In one, a nurse sits down with an 82-year-old patient, Marvin Millar, who frowns and mumbles incoherently as she asks him identify everyday objects such as a bracelet and a pencil, which he is unable to do.

But five minutes after being injected with etanercept – according to the film which was supplied and edited by the clinic – he greets his wife. Visibly shocked, she says he has not recognised her for years. Mr Miller then hugs her.

In a separate interview, also supplied by the clinic, she describes his improvements four weeks later, saying he makes sense 90 per cent of the time now, compared with none of the time before treatment started. After the BBC reported the claims yesterday, callers jammed the Alzheimer's Society's helpline demanding details of the treatment. Experts urged caution, warning that the drug had been tried on only a very few patients and, crucially, had not been tested against a placebo in a randomised controlled trial.

Etanercept is not a new drug, but this is a novel use of it. The California researchers injected it between the cervical vertebrae at the back of the neck, just below the skull, directly into the spinal column. Tilting is thought to encourage the drug to cross the blood-brain barrier. In arthritis, the drug blocks a chemical – tumour necrosis factor-alpha (TNF) – which causes inflammation and pain in the joints. It is thought TNF may also influence inflammation in the brain, and that by damping down the process the drug may preserve brain function. Professor Edward Tobinick, who is leading the research, said: "What we see is an improvement in ability to think and calculate, memory improves, verbal ability improves, [patients] find words easier, they seem happier and we often also see an improvement in gait in patients whose gait is affected."

The researchers said improvement usually continued with weekly injections until it reached a plateau at about three months. Some patients had been taking it for three years. But they have only published details of 15 patients in a pilot study.

An estimated 400,000 people suffer from Alzheim-er's disease in the UK and claims for new treatments are seized upon by relatives, desperate for any straw to clutch. Suzanne Sorenson, head of research at the Alzheimer's Society, said she had been sceptical of the claims when she heard about them in January but having seen the film foot-age, considered it was now time to run a trial.

On the surface these results are exciting but we need to treat the study with caution," she said. "There are large gaps in the research, which used a small pilot group. We cannot draw conclusions until a controlled trial is carried out." Clive Holmes, professor of biological psychiatry at Southampton University, a centre for research on dementia, said he was prepared to test the drug.

"The evidence from basic science suggests it is worth giving these drugs a trial to see if there is evidence on a larger basis," he said. The elusive search for a cure *A hundred years after Alzheimer's disease was discovered, a cure for the progressive neurodegenerative condition remains a distant dream. Despite dramatic breakthroughsin other areas, there has been little to celebrate in Alzheimer's. The main advance has been drugs to control symptoms such as agitation and restlessness. But restoring memory and cognitive ability has proved much harder.

The condition is caused by an accumulation of protein deposits in the brain which produce the symptoms of dementia. There are three drugs with claims to halt the disease's progression (though not reverse it), Aricept, Reminyl and Exelon. In 2005 their NHS use was restricted to the moderate stage of the disease – as opposed to early or late stages – by the National Institute for Clinical Excellence because of their limited effect.